MASQUELIER's OPCs offer vascular benefits.

MASQUELIER's OPCs (from i. BioCeuticals) produces a significant improvement of overall vascular health compared to placebo, according to a study performed by the Department of Toxicology of Maastricht University, published in PLOS One in December 2011.

This research project confirms the vast amount of scientific work performed since professor Jack Masquelier first isolated the active principles of MASQUELIER's Original OPCs. The study showed a significant decrease in serum total cholesterol and LDL. Additionally, after 8 weeks of supplementation, the ratio of glutathione to glutathione disulphide in erythrocytes rose from baseline by 22% in the supplemented subjects. The researchers also observed that MASQUELIER's OPCs exerts anti-inflammatory effects in blood toward ex vivo added bacterial endotoxin and significantly reduces expression of inflammatory genes in leukocytes.

Conversely, alterations in biomarkers such as platelet aggregation, plasma levels of nitric oxide surrogates, endothelin-1, C-reactive protein, and prostaglandin F2alpha, did not reach statistical significance. However, integrating all measured effects into a global vascular health index and taking into account that the trial was performed with healthy subjects, it was concluded that MASQUELIER's OPCs produces a significant improvement of overall vascular health compared to placebo. For further information: www.inc-opc.com